Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
Start of experimental phase: 05 July 2016 End of experimental phase: 17 August 2016 Study completion :21 October 2016
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2016
Report date:
2016

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
Version / remarks:
adopted on 17 December 2001
Deviations:
no
GLP compliance:
yes
Test type:
acute toxic class method
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
2,2'-[1,2-ethanediylbis(oxy)]bis(ethanethiol)
EC Number:
239-044-2
EC Name:
2,2'-[1,2-ethanediylbis(oxy)]bis(ethanethiol)
Cas Number:
14970-87-7
Molecular formula:
C6H14O2S2
IUPAC Name:
2,2'-[1,2-ethanediylbis(oxy)]bis(ethanethiol)
Test material form:
liquid

Test animals

Species:
rat
Strain:
Sprague-Dawley
Sex:
female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
Species and strain Rat, Hsd: Sprague Dawley SD
Sex: Females (nulliparous and non-pregnant)
Age: 7-8 weeks old; 6-7 weeks old (differently from what specified in the Study Protocol)
Supplier: Envigo RMS s.r.l., San Pietro al Natisone (UD), Italy
Date of arrival: 23 June 2016; 14 July 2016
Weight range at arrival: 170-178 grams; 163.8-168.8 grams
Acclimatisation period: At least 5 days
Veterinary health check: During acclimatisation period

ENVIRONMENTAL CONDITIONS
Animals per cage: 3 during the study; up to 5 during acclimatisation
Housing: Polisulphone solid bottomed cages measuring 59.5×38×20 cm with nesting material provided into suitable bedding bags
Cage control: Daily inspected and changed as necessary (at least 3 times/week)
Water: Drinking water supplied to each cage via a water bottle
Water supply: ad libitum
Diet: 4 RF 18 (Mucedola S.r.l., Via G. Galilei, 4, 20019, Settimo Milanese (MI) Italy)
Diet supply: ad libitum throughout the study except for the dosing procedure indicated in section 4.2.2
Room lighting: Artificial (fluorescent tubes), daily light/dark cycle of 12/12 hours
Air changes Approximately 15 to 20 air changes per hour
Temperature range: 22 °C±2 °C
Relative humidity range: 55%±15%

Administration / exposure

Route of administration:
oral: gavage
Details on oral exposure:
VEHICLE
- Concentration in vehicle: 30 and 5mg/mL
- Amount of vehicle (if gavage): 10 mL/kg

CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose:
Doses:
300 mg/kg; 50 mg/kg
No. of animals per sex per dose:
6 Females at 300 mg/kg; 6 females at 50 mg/kg
Control animals:
no
Details on study design:
- Duration of observation period following administration: 14 days
- Frequency of observations and weighing:Animals were observed for clinical signs the day of dosing: on dosing, approximately 0.5 hour, 2 hours and 4 hours after dosing daily thereafter for a total of 14 days.
All animals were weighed at allocation to the study (Day -1), on the day of dosing (Day 1) and
on Days 2, 8 and 15.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight,

Results and discussion

Effect levels
Key result
Sex:
female
Dose descriptor:
LD50
Effect level:
> 50 - <= 300 mg/kg bw
Based on:
test mat.
Mortality:
One of the three animals initially dosed at 300mg/kg (Step 1) was found dead on Day 2 of study. Two animals were found dead, in the second group dosed at the same dose level. No mortality occurred in any of six animals dosed at 50 mg/kg.
Clinical signs:
Tremors, ataxia and piloerection were observed in all animals of the step I (dosed at 300 mg/kg). Surviving animals recovered from these signs on Day 2 of study.
Tremors, ataxia and muscular rigidity were observed in all animals of the step II (dosed at 300 mg/kg). Surviving animal recovered from these signs on Day 2 of study.
No clinical sign was seen in all animals dosed at 50 mg/kg.
Body weight:
Changes in body weight observed during the study were within the expected range for this strain and age of animals.
Gross pathology:
No abnormalities were observed at necropsy examination performed on termination of the observation period and in the animals found dead.

Applicant's summary and conclusion

Interpretation of results:
Category 3 based on GHS criteria
Conclusions:
These results demonstrate the acute toxicity expected (ATE) to be lower than 300mg/kg body weight, but higher than 50mg/kg body weight.
Executive summary:

The acute toxicity of DIMERCAPTO-1,8-DIOXA-3,6-OCTANE (DMDO) was investigated following a single oral administration to the Sprague-Dawley rat followed by a 14-day observation period.

Experimental procedures were in agreement with the OECD guideline Number 423 (adopted on 17 December 2001). A first group of 3 female animals was dosed at a level of 300mg/kg (Step 1), dose level selected on the basis of available information. A second group, similarly composed, was then dosed at the same dose level (Step 2). Since two animals died in Step 2, according to the step-wise procedure foreseen in the relevant guideline, a third group of 3 females was dosed at the lower dose level of 50mg/kg (Step 3). Finally an additional group, similarly composed, was dosed at the same dose level (Step 4). No further doses were investigated, since the objective of the study had been achieved.

All animals dosed at 300mg/kg (Step 1) showed tremors, ataxia and piloerection. One animal was found dead and the others recovered from these signs on Day 2 of study. Tremors, ataxia and muscular rigidity were observed in all animals dosed at the same dose level (Step 2). Two animals were found dead, while the third one recovered on Day 2 of study. No mortality occurred and no clinical sign was seen in all animals dosed at 50mg/kg (Step 3 - Step 4). Body weight changes recorded during the study were within the expected range for this strain and age of animals. No abnormalities were observed at necropsy examination performed on termination of the observation period and in the animals found dead.

These results demonstrate the acute toxicity expected (ATE) to be lower than 300mg/kg body weight, but higher than 50mg/kg body weight.